Oxford Respiratory Trials Unit (ORTU)
About ORTU
The Oxford Respiratory Trials Unit (ORTU) specialises in the design, delivery, analysis, and administration of trials across the broad scope of Respiratory Medicine and Respiratory Diseases.
We are part of the UKCRC Registered Oxford Collaborative Clinical Trials Unit (OxCCTU), which brings together ORTU, the Primary Care Clinical Trials Unit, Oxford Vaccine Group, and the Jenner Institute. UKCRC registration recognises our ability to centrally co-ordinate multi-centre clinical trials, including taking full responsibility for the trial lifecycle from development to the analysis and dissemination of results. This also signifies that we have well-established and rigorous systems in place to ensure all clinical trials are conducted and delivered to the highest quality standards. You can find more information about the UKCRC at https://ukcrc-ctu.org.uk/.
OxCCTU manage trials across a wide range of therapeutic areas, whilst fostering a joined-up approach to our use of resources and expertise, resulting in synergies that allow us to conduct efficient yet focused research.
ORTU runs national and international trials related to our academic areas of interest, as well as supporting trials led by other teams and industry. Our scope of work includes clinical trials at all phases, including translational studies, phase II discovery studies, and multi-centre definitive randomised trials.
We partner with a broad range of academic funders, including the National Institute of Health Research (NIHR), Medical Research Council (MRC), British Lung Foundation, National Cancer Research Institute (NCRI), and Cancer Research UK (CRUK), as well as partners in industry. Key funding for ORTU is derived from the NIHR Research Delivery Network (RDN) and the Oxford NIHR Biomedical Research Centre.
ORTU publications
-
TCF1 and LEF1 promote B-1a cell homeostasis and regulatory function.
Journal article
Shen Q. et al, (2025), Nature
-
"Not-So-Simple": Rethinking Pleural Effusions in Cancer, Heart Failure, and Pneumonia.
Journal article
Bhatnagar M. and Rahman NM., (2025), Chest, 168, 290 - 291
-
Burden of Respiratory Syncytial Virus infection in older adults hospitalised in England during 2023/24
Journal article
Symes R. et al, (2025), Journal of Infection, 106570 - 106570
-
Proposed framework for triage of putative germline variants detected via tumour genomic testing in UK oncology practice.
Journal article
McVeigh TP. et al, (2025), Journal of medical genetics
-
Thoracic Ultrasound – EFSUMB Training Recommendations, a position paper
Journal article
Laursen CB. et al, (2025), Ultraschall in der Medizin - European Journal of Ultrasound
-
A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration
Journal article
Nguyen BT. et al, (2025), The Journal of Infectious Diseases, 231, e1080 - e1090
-
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)
Journal article
Kanellakis NI. et al, (2025), European Respiratory Journal, 66, 2500010 - 2500010
-
Inherited Susceptibility to Cancer: Past, Present and Future.
Journal article
Hodgson SV. et al, (2025), Annals of human genetics